(Q82754347)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21134451%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

title

Increased potency of an inactivated trivalent polio vaccine with oil-in-water emulsions (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21134451%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21134451%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

3

Mark A Pallansch

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21134451%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

5

Steven G Reed

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21134451%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

4

Rhea N Coler

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21134451%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

author name string

Susan L Baldwin

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21134451%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

Martin Friede

series ordinal

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21134451%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

publication date

4 December 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21134451%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21134451%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21134451%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21134451%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

page(s)

644-649

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21134451%20AND%20SRC:MED&resulttype=core&format=json

New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis

17 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

7 January 2021

Future of polio vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

Role of injectable and oral polio vaccines in polio eradication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

Production, testing and perspectives of IPV and IPV combination vaccines: GSK biologicals' view

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

Randomized controlled clinical trial of fractional doses of inactivated poliovirus vaccine administered intradermally by needle-free device in Cuba

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

Fractional doses of inactivated poliovirus vaccine in Oman

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

A vaccine manufacturer's approach to address medical needs related to seasonal and pandemic influenza viruses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

Squalene emulsions for parenteral vaccine and drug delivery

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

7 January 2021

Safety of MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

1,25-dihydroxyvitamin d3 enhances systemic and mucosal immune responses to inactivated poliovirus vaccine in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

CpG oligodeoxynucleotides are a potent adjuvant for an inactivated polio vaccine produced from Sabin strains of poliovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

Combined immunization of infants with oral and inactivated poliovirus vaccines: results of a randomized trial in The Gambia, Oman, and Thailand. WHO Collaborative Study Group on Oral and Inactivated Poliovirus Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

Polio eradication: the OPV paradox

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

Inactivated poliovirus vaccine and the final stages of poliovirus eradication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

Inactivated Polio Vaccine (IPV): a strong candidate vaccine for achieving global polio eradication program

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

Pediatric combined formulation DTaP-IPV/Hib vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

Concomitant administration of a virosome-adjuvanted hepatitis a vaccine with routine childhood vaccines at age twelve to fifteen months: a randomized controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

Simultaneous injection of hepatitis B vaccine with BCG and killed poliovirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

Further investigations on the immunogenic activity of aqueous and aluminum oxide adsorbed inactivated poliovirus vaccines in Macaca mulatta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

Vitamin A supplementation and retinoic acid treatment in the regulation of antibody responses in vivo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

Use of poliomyelitis virus vaccine in light mineral oil adjuvant in a community immunization program and report of reactions encountered

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

Control of Influenza and Poliomyelitis with Killed Virus Vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

World wide experience with inactivated poliovirus vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.11.043

10.1016/J.VACCINE.2010.11.043

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21134451%20AND%20SRC:MED&resulttype=core&format=json

17 January 2020

1 reference